Compare BridgeBio Pharma Inc (BBIO) vs ProShares UltraPro QQQ ETF (TQQQ) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
BridgeBio Pharma Inc vs ProShares UltraPro QQQ ETF — how do they compare? BridgeBio Pharma Inc trades at $84.24 (market cap $16.36B), while ProShares UltraPro QQQ ETF trades at $75.04. The key difference: BridgeBio Pharma Inc is trading nearer its 52-week high, ProShares UltraPro QQQ ETF nearer its low. Which is the better fit depends on your goals.
| BBIO | TQQQ | |
|---|---|---|
Market Cap | $16.36B | — |
Sector | Health | Leveraged / Inverse |
52-Week High | $90.17 | $87.22 |
52-Week Low | $47.29 | $37.89 |
Enterprise Value | $18.14B | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
BridgeBio Pharma (BBIO) trades at $84.57, down slightly by 0.12% on the day, with a bullish technical signal from moving averages but mixed oscillators. The company reported Q2 2026 revenue growth driven by Attruby sales, though it missed EPS estimates. With a high P/S ratio of 22.77 and negative profitability metrics, the stock is priced for future growth, supported by strong analyst buy ratings and a $104.56 consensus price target.
The outlook hinges on successful product launches and regulatory approvals, with three potential launches expected within 12 months offering significant upside. Key risks include persistent cash burn, high debt, and execution challenges in bringing new treatments to market, which could pressure the stock if milestones are missed.
TQQQ trades at $74.96, up 1.59% with a bullish technical signal supported by moving averages. The leveraged ETF shows strong momentum from AI-driven tech sector performance, though oscillators indicate neutral short-term sentiment. Recent institutional buying activity and positive media coverage highlight continued investor interest in Nasdaq-100 exposure through this 3x leveraged vehicle.
The outlook remains positive given robust tech earnings and AI infrastructure spending, but volatility decay and leverage risks require careful position sizing. TQQQ offers amplified Nasdaq-100 returns during bull markets but faces significant downside risk during market corrections, making it suitable for tactical rather than long-term holdings.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About BridgeBio Pharma Inc
BridgeBio Pharma Inc is involved in identifying advance transformative medicines to treat patients who suffer from Mendelian diseases, which are diseases that arise from defects in a single gene, and cancers with clear genetic drivers. Its product pipeline categories include Mendelian, Genetic Dermatology, Oncology, and Gene therapy.
Read more on BBIO →About ProShares UltraPro QQQ ETF
TQQQ is a leveraged ETF that seeks daily investment results, before fees and expenses, that correspond to three times (3x) the daily performance of the Nasdaq-100 Index. It is one of the most liquid and actively traded instruments in the market, designed for sophisticated traders to amplify short-term bullish exposure to large-cap non-financial growth stocks, predominantly in the technology and communication sectors.
Read more on TQQQ →
